The pharmacokinetics and interactions of new antiepileptic drugs - An overview

被引:35
作者
Bialer, M
机构
[1] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, Dept Pharmaceut, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, Sch Pharm, Fac Med, David R Bloom Ctr Pharm, IL-91120 Jerusalem, Israel
关键词
antiepileptic drugs; pharmacokinetics; interactions;
D O I
10.1097/01.ftd.0000179854.16846.67
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 [基础医学];
摘要
In the past decade 10 new antiepileptic drugs (AEDs) have been introduced: felbamate, gabapentin, lamotrigine, levetiracetem, oxcarbazepine, pregabalin, tiagabine, topiramate, vigabatrin, and zonisamide. The pharmacokinctics (PK) of these new AEDs as well as their potential for drug interactions are reviewed in this article. In general, new AEDs have better PK profies and are less involved in drug interactions than the 4 established AEDs: phenobarbital, phenytoin, carbamazepine, and valproic acid. However, in spite of the large therapeutic arsenal of old and new AEDs, about 30% of epileptic patients are still not seizure-free, and thus, there is a substantial need to develop new AEDs.
引用
收藏
页码:722 / 726
页数:5
相关论文
共 28 条
[1]
ABDELRAHMAN SM, 2000, METABOLIC DRUG INTER, P673
[2]
A mechanistic approach to antiepileptic drug interactions [J].
Anderson, GD .
ANNALS OF PHARMACOTHERAPY, 1998, 32 (05) :554-563
[3]
Unmasking the dynamic interplay between efflux transporters and metabolic enzymes [J].
Benet, LZ ;
Cummins, CL ;
Wu, CY .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 277 (1-2) :3-9
[4]
Changes in plasma protein binding have little clinical relevance [J].
Benet, LZ ;
Hoener, BA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :115-121
[5]
Progress report on new antiepileptic drugs: a summary of the Seventh Eilat Conference (EILAT VII) [J].
Bialer, M ;
Johannessen, SI ;
Kupferberg, HJ ;
Levy, RH ;
Perucca, E ;
Tomson, T .
EPILEPSY RESEARCH, 2004, 61 (1-3) :1-48
[6]
Pharmacokinetic interactions of topiramate [J].
Bialer, M ;
Doose, DR ;
Murthy, B ;
Curtin, C ;
Wang, SS ;
Twyman, RE ;
Schwabe, S .
CLINICAL PHARMACOKINETICS, 2004, 43 (12) :763-780
[7]
Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine [J].
Britzi, M ;
Perucca, E ;
Soback, S ;
Levy, RH ;
Fattore, C ;
Crema, F ;
Gatti, G ;
Doose, DR ;
Maryanoff, BE ;
Bialer, M .
EPILEPSIA, 2005, 46 (03) :378-384
[8]
Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects [J].
Doose, DR ;
Wang, SS ;
Padmanabhan, M ;
Schwabe, S ;
Jacobs, D ;
Bialer, T .
EPILEPSIA, 2003, 44 (04) :540-549
[9]
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition [J].
Dresser, GK ;
Spence, JD ;
Bailey, DG .
CLINICAL PHARMACOKINETICS, 2000, 38 (01) :41-57
[10]
Induction of drug metabolising enzymes - Pharmacokinetic and toxicological consequences in humans [J].
Fuhr, U .
CLINICAL PHARMACOKINETICS, 2000, 38 (06) :493-504